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Introduction: Malignant mesothelioma (MM) is an aggressive neo-
plasm causatively associated with exposure to asbestos. MM is rarely 
responsive to conventional cytotoxic drugs, and the outcome remains 
dismal. It is, therefore, necessary to identify the signaling pathways 
that drive MM and to develop new therapeutics specifically targeting 
the molecules involved.
Methods: We performed comprehensive RNA sequencing of 12 MM 
cell lines and four clinical samples using so-called next-generation 
sequencers.
Results: We found 15 novel fusion transcripts including one derived 
from chromosomal translocation between the large tumor suppres-
sor 1 (LATS1) and presenilin-1 (PSEN1) genes. LATS1 is one of 
the central players of the emerging Hippo signaling pathway. The 
LATS1–PSEN1 fusion gene product lacked the ability to phosphory-
late yes-associated protein and to suppress the growth of a MM cell 
line. The wild-type LATS1 allele was undetectable in this cell line, 
indicating two-hit genetic inactivation of its tumor suppressor func-
tion. Using pathway-targeted exon sequencing, we further identified 
a total of 11 somatic mutations in four Hippo pathway genes (neu-
rofibromatosis type 2 [NF2], LATS2, RASSF1, and SAV1) in 35% (8 
of 23) of clinical samples. Nuclear staining of yes-associated protein 
was detected in 55% (24 of 44) of the clinical samples. Expression 
and/or phosphorylation of the Hippo signaling proteins, RASSF1, 
Merlin (NF2), LATS1, and LATS2, was frequently absent.
Conclusions: The frequent alterations of Hippo pathway molecules 
found in this study indicate the therapeutic feasibility of targeting 
this pathway in patients with MM.
Key Words: Malignant mesothelioma, Next-generation sequencer, 
Hippo pathway, LATS1, Fusion gene.
(J Thorac Oncol. 2015;10: 844–851)
Malignant mesothelioma (MM) is a highly aggressive neo-plasm that arises from mesothelial cells covering the sur-
faces of the pleura, peritoneum, and pericardium. Etiologically, 
MM is associated with exposure to asbestos and other fibrous 
minerals.1 Surgical resection is theoretically the most effec-
tive treatment for any solid malignant tumors, but complete 
removal of MM is rarely attainable because of its dissemina-
tive and invasive growth.2 Although there has been significant 
progress in the development of combination chemotherapies, 
MM rarely responds to conventional cytotoxic drugs, and the 
outcome remains dismal.3 It is, therefore, necessary to develop 
new therapeutics specifically targeting molecules essential for 
the development and/or progression of MM.
The Hippo signaling pathway is a regulator of organ size 
and tissue regeneration.4 Somatic mutations of two genes in 
the Hippo signaling pathway have been reported in MM cells.5 
The NF2 gene,6,7 which encodes the merlin tumor suppressor 
protein, shows the highest frequency of mutation. Deletion 
and mutation of large tumor suppressor 2 (LATS2) have been 
identified in several MM cell lines and clinical samples, and 
its tumor suppressive role has been demonstrated in vitro.5 
However, many other signaling molecules are known to regu-
late the Hippo pathway,8 and their spectrum of aberrations and 
clinical relevance in MM remain largely unknown.
The development of high-throughput sequencers (or so-
called next-generation sequencers [NGS]) has made it possible 
to rapidly survey oncogenic and tumor-suppressive signaling 
molecules in various cancers on a genome-wide basis.9 In the 
present study, we investigated the MM genome using unbi-
ased whole-exon (exome) and RNA (transcriptome) sequenc-
ing and found a novel gene fusion between the LATS1 and 
presenilin-1 genes (LATS1–PSEN1). The fusion gene product 
lacked the kinase activity of LATS1, and the LATS1 locus was 
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inactivated by a two-hit genetic event. We then focused on the 
Hippo signaling pathway and sequenced all exons of the 40 
genes known to constitute the pathway.
MATERIALS AND METHODS
Cell Lines and Clinical Samples
The 19 MM cell lines used in this study and their suppli-
ers are listed in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A805). An immortalized 
mesothelial cell line, MeT-5A, was purchased from the American 
Type Culture Collection (Manassas, VA). The human embryonic 
kidney cell line HEK293 was obtained from the Health Science 
Research Resources Bank (Osaka, Japan). The cell lines were 
maintained in accordance with the suppliers’ recommendations.
The clinical and pathological characteristics of 23 
patients whose fresh frozen tissue samples were analyzed by 
NGS are summarized in Supplementary Table 2 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A805). Formalin-
fixed paraffin-embedded tissue sections were collected from 
44 MM patients (including the aforementioned 23 patients) 
who underwent panpleuropneumonectomy or pleural biopsy 
at the National Cancer Center (NCC) Hospital (Tokyo, Japan) 
between 1995 and 2012 with written informed consent. This 
study was conducted with approval from the Institutional 
Review Board of the National Cancer Center.
DNA and RNA Preparation
Genomic DNA was extracted using the DNeasy Blood 
and Tissue kit (Qiagen, Hilden, Germany) in accordance with 
the manufacturer’s protocol. Total RNA was extracted using 
TRIzol reagent (Invitrogen, Carlsbad, CA) or RNeasy Mini 
Kit columns (Qiagen) using the manufacturer’s protocol. The 
quality of RNA was assessed by an Agilent 2100 Bioanalyzer 
FIGURE 1.  Identification of the 
LATS1–PSEN1 fusion gene. A, Graphic 
representation of RNA sequencing 
and comparative genomic hybrid-
ization data for MSTO-211H cells. 
Chromosome ideograms and copy 
number variation are shown in the 
outer and middle layers, respec-
tively. Chromosomal translocation 
is shown in the central layer. The 
LATS1–PSEN1 fusion is shown in 
red, and the SLIT2-AC006052.1 and 
TRAPPC9-GBA3 fusions are shown 
in blue. B, Nucleotide and deduced 
amino acid sequences at the break/
fusion point of the LATS1–PSEN1 
transcript. C, Schematic representa-
tion of the deduced domain structure 
of wild-type LATS1 and LATS1–PSEN1 
proteins. Wild-type LATS1 contains 
the ubiquitin-associated domain 
(amino acids 100–141), protein 
kinase domain [705–1010], and 
AGC-kinase C-terminal domain 
[1010–1090]. D, Ideogram showing 
the chromosomal translocation of 
LATS1 (chromosomes 6 at q25.1) and 
PSEN1 (chromosome 14 at q24.3). E, 
Comparative genomic hybridization 
analysis of chromosome 6 of MSTO-
211H cells. F, Expression level of each 
exon of the LATS1 and PSEN1 genes 
determined by counting the number 
of reads in RNA sequencing.
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(Agilent Technologies, Santa Clara, CA). All samples were 
confirmed to show an RNA Integrity Number of greater than 
7.0. The quantity of genomic DNA and total RNA was deter-
mined using a NanoDrop 2000 Spectrophotometer (Thermo 
Scientific, Rockford, IL).
Whole-Exon Sequencing
Three micrograms of genomic DNA were used for con-
struction of libraries. The quality of the libraries was assessed 
using an Agilent 2100 Bioanalyzer. Whole human exons were 
captured using a SureSelectXT Human All Exon 50 Mb Target 
Enrichment kit (Agilent) in accordance with the manufacturer’s 
instructions (Protocol 1.1.1.). Enriched libraries were sequenced 
using HiSeq 2000 and a TruSeq SBS Kit v3-HS (Illumina). Base 
calling was performed using the Illumina Pipeline (CASAVA 
v1.8) with default parameters. Only paired-end (100 bases each) 
sequence reads that passed the quality control were mapped to 
the human reference genome build hg19 (UCSC hg19) using 
BWA (http://bowtie-bio.sourceforge.net/)10 with default param-
eters. Elimination of sequencing artifacts and identification 
of novel variants were performed as described previously.9 
Thresholds for identifying the final sets of variants calls were 
defined as follows: SNP quality ≥228; coverage ≥20; reads 20–
2000; frequency ≥10%; not deposited in the dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/, v137).
RNA Sequencing
Six micrograms (cell lines) and 14–36 µg (patient 
samples) of total RNA were used for construction of libraries 
using the TruSeq RNA Sample Preparation Kit (v2, Illumina). 
The libraries were used to generate clustered flow cells on 
cBot using a TruSeq PE Cluster Kit v2. Paired-end sequenc-
ing (75 base pair [bp] each) was performed on an Illumina 
Genome Analyzer IIx sequencer using a TruSeq SBS Kit v5.
The Illumina software pipeline was used for processing 
of the image data into raw sequencing data (SCS v2.9 and 
CASAVA v1.8.1). Only sequence reads marked as “passed fil-
tering” were subjected to selection of fusion gene candidates 
using the deFuse program.11
Pathway-Targeted Exon Sequencing
The entire exons of the 40 Hippo pathway genes (listed in 
Supplementary Table 3, Supplemental Digital Content 1, http://
links.lww.com/JTO/A805) and their flanking sequences were 
enriched using custom-made SureSelectXT Target Enrichment 
arrays (Agilent). The enriched libraries were sequenced on a 
HiSeq 2000 using a TruSeq SBS Kit v3-HS to generate 100-
bp pair-end reads. Criteria used for selecting the final set of 
variants calls were identical to those for the aforementioned 
whole-exon sequencing. (Additional materials and methods 
are available in Supplementary Methods, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A806).
RESULTS
Landscape Overview of the MM Genome
Initially, we performed whole-exon sequencing of six 
MM cell lines (NCI-H28, NCI-H2452, NCI-H2052, MSTO-
211H, ACC-MESO-1, and ACC-MESO-4). Under stringent 
selection criteria, we identified a total of 1030 alterations in 952 
genes (Supplementary Table 4, Supplemental Digital Content 
1, http://links.lww.com/JTO/A805) that were not deposited 
in the dbSNP database. These included genes involved in 
the Hippo (FTA1, FTA2, RASSF22, and RASSF6), mitogen-
activated protein kinase (PLA2G4B, CACNA1S, CACNB3, 
CACNG6, FGFR2, MAP3K4, PPM1A, and PTPN5), Wnt 
(EP300, ROCK2, APC2, FZD1, and FZD10), nuclear factor-
kappa B (FADD and IRAK1), and angiogenesis (PLA2G4B, 
TABLE 1.  Fusion Transcripts Detected by RNA Sequencing
No Sample
5′ Gene 3′ Gene
Gene Ensembl Gene IDa Strand. Chr Location Gene Ensembl Gene IDa Strand. Chr Location
1 NCI-H28 USP4 ENSG00000114316 + 3 Exon 6 RNY3P8 ENSG00000223298 + 13 Exon 1
2 NCI-H2452 CNOT10 ENSG00000182973 + 3 Exon 12 OSBPL10 ENSG00000144645 + 3 Introns 2 and 3
3 NCI-H2452 GSR ENSG00000104687 + 8 Exon 3 NRG1 ENSG00000157168 + 8 Introns 1 and 2
4 NCI-H2452 TAF15 ENSG00000172660 + 17 Exon 1 MPP2 ENSG00000108852 − 17 Exon 4
5 MSTO-211H SLIT2 ENSG00000145147 + 4 Exon 1 AC006052.1 ENSG00000251220 − 4 Downstream
6 MSTO-211H LATS1 ENSG00000131023 + 6 Exon 7 PSEN1 ENSG00000080815 + 14 Exon 8
7 MSTO-211H PSEN1 ENSG00000080815 + 14 Exon 8 LATS1 ENSG00000131023 + 6 Introns 5 and 6
8 MSTO-211H TRAPPC9 ENSG00000167632 + 8 Exon 16 GBA3 ENSG00000249948 + 4 Introns 1 and 2
9 ACC-MESO-4 VRK1 ENSG00000100749 + 14 Exon 8 AL445885.1 ENSG00000246084 + 14 Upstream
10 NO36 RPRD1A ENSG00000141425 + 18 Exon 1 FHOD3 ENSG00000134775 + 18 Introns 12 and 13
11 Mero-25 TP53 ENSG00000141510 + 17 Exon 9 HSF2BP ENSG00000160207 − 21 Exon 4
12 Mero-25 ATP9A ENSG00000054793 + 20 Exon 4 KAZN ENSG00000189337 − 1 Introns 1–2
13 LO68 PARD3B ENSG00000116117 + 2 Exon 2 SPHKAP ENSG00000153820 − 2 Exon 2
14 Mero-14 JHDM1D ENSG00000006459 + 7 Exon 4 RP1-150O5.3 ENSG00000235052 + 1 Upstream
15 CT-11T STAT1 ENSG00000115415 + 2 Exon 18 CDRT1 ENSG00000241322 − 17 Exon 4
aEnsembl gene ID registered in the Ensembl database (http://www.ensembl.org/index.html).
Chr, chromosome.
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KDR, VEGFA, and VEGFC) pathways. Due to unavailability 
of the normal corresponding counterparts, we were unable to 
determine whether these alterations were somatic mutations.
Copy number variation (CNV) data were also obtained 
from the same six cell lines using array-based comparative 
genomic hybridization technology. The entire results of the 
whole-exon sequencing and CNV analyses are summarized in 
Circos plots12 (Fig. 1A and Supplementary Fig. 1, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A807).
Identification of the LATS1–PSEN1 Fusion Gene
We next performed RNA sequencing of 12 MM cell lines 
(including the aforementioned six cell lines) and pair samples 
of normal and tumor tissue from four MM patients (CT-1, -7, 
-9, and -11) and identified a total of 15 novel fusion transcripts 
(Table 1). All of the 15 fusion genes were subsequently vali-
dated by reverse-transcriptase polymerase chain reaction across 
their relevant exon–exon boundaries and dideoxynucleotide 
Sanger sequencing (Supplementary Fig. 2A, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A807 and data not 
shown). The interchromosomal and intrachromosomal translo-
cations responsible for them frequently involved chromosomes 
2, 3, 7, 8, and 17 (Supplementary Fig. 2B, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A807).
Of the 15 fusion transcripts, three (LATS1–PSEN1, 
PSEN1–LATS1, and VRK1–AL445885.1) involved protein 
tyrosine kinase genes. The LATS1 gene product is one of 
the mainstream signaling molecules of the Hippo pathway. 
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FIGURE 2.  Functional significance of the 
LATS1–PSEN1 fusion gene. A, HEK293 cells 
were transfected with pcDNA3.1-LATS1-
V5, pcDNA3.1-LATS1–PSEN1-V5, or a 
relevant empty plasmid. Twenty-four hours 
later, the expression of wild-type LATS1 
and LATS1–PSEN1 proteins was confirmed 
by immunoprecipitation (IP) with anti-V5 
antibody or control IgG and blotting with 
anti-V5 antibody. The immunoprecipitates 
were then incubated with glutathione 
S-transferase-YAP recombinant protein 
at 30°C for 30 minutes and analyzed by 
blotting with antiphosphorylated YAP and 
anti-YAP antibodies. B, MSTO-211H cells 
were transfected with pcDNA3.1-LATS1, 
pcDNA3.1-LATS1–PSEN1, or an empty 
vector (Vector). Twenty four hours later, 
cell lysates were extracted and blotted with 
antiphosphorylated YAP (p-YAP), anti-YAP, 
anti-LATS1, and anti-γ-tubulin (loading 
control) antibodies. Molecular masses (in 
kilodaltons) are shown to the right. C, 
Immunofluorescence microscopy analy-
sis of MSTO-211H cells transfected with 
pcDNA3.1-LATS1-V5 (LATS1), pcDNA3.1-
LATS1–PSEN1-V5 (LATS1–PSEN1), or an 
empty vector (Vector) with anti-V5 and 
anti-YAP1 antibodies. Nuclei were stained 
with TOTO-3 Iodide. Bar, 10 μm. D and E, 
Colony formation (D) and soft-agar colony 
formation (E) of MSTO-211H cells trans-
fected with pcDNA3.1-LATS1, pcDNA3.1-
LATS1–PSEN1, or an empty vector (Vector) 
and selected with geneticin (G418) for 14 
days.
848 Copyright © 2015 by the International Association for the Study of Lung Cancer
Miyanaga et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 5, May 2015
Homozygous deletion and mutations of LATS2 have been 
detected in several MM cell lines and clinical samples,5 but 
no genetic alteration has been reported in the closest member 
of this gene family, LATS1. The LATS1–PSEN1 transcript was 
a tail-to-tail fusion between exon 7 of LATS1 and exon 8 of 
PSEN1 (Fig. 1B), and this was deduced to encode a truncated 
protein lacking the C-terminal AGC-kinase domain and part 
of the protein kinase domain (Fig. 1C).
The LATS1 and PSEN1 genes are located on chromo-
somes 6 and 14, respectively (Fig. 1D). The genomic break/
fusion point was identified in intron 7 of LATS1 and intron 
8 of PSEN1 by Sanger sequencing (Supplementary Fig. 
3A, Supplemental Digital Content 3, http://links.lww.com/
JTO/A807). The interchromosomal rearrangement involv-
ing the LATS1 and PSEN1 loci (Fig. 1A) was confirmed by 
fluorescence in situ hybridization (Supplementary Fig. 3B, 
Supplemental Digital Content 3, http://links.lww.com/JTO/
A807). Comparative genomic hybridization array analysis 
revealed loss of the LATS1 gene locus (Fig. 1E). The LATS1 
gene has eight exons, but transcripts only from exons 1 to 7 
were detected by RNA sequencing (Fig. 1F), indicating that 
the normal allele of LATS1 is not transcribed. These results 
indicate that the alleles of LATS1 were inactivated by a dele-
tion and rearrangement double-hit.
Loss of LATS1 Tumor Suppressor Function
V5-tagged wild-type (LATS1-V5) and fusion (LATS1–
PSEN1-V5) LATS1 were expressed in HEK 293 cells 
(Fig. 2A) and purified with anti-V5 antibody. Glutathione 
S-transferase-tagged yes-associated protein (YAP) was phos-
phorylated by incubation with the purified wild-type LATS1 
protein, but not with LATS1–PSEN1, indicating that the 
fusion gene product lost its kinase activity probably because 
of partial loss of its kinase domain (Fig. 1C). Consistently, 
phosphorylated YAP (p-YAP) was detected in MSTO-211H 
cells transfected with an expression vector encoding wild-
type LATS1, but not in cells transfected with one encoding 
LATS1–PSEN1 (Fig. 2B).
The YAP is a transcriptional coactivator and serves 
as one of the downstream effectors of Hippo signaling. 
When cells become confluent, YAP is phosphorylated 
by LATS1/2 and trapped in the cytoplasm, resulting in 
silencing of transcriptional activity and inhibition of cell 
growth. MSTO-211H cells are genetically deficient in 
LATS1, and the YAP was localized in the nuclei even at 
high cell density (top, Fig. 2C and Supplementary Fig. 
4, Supplemental Digital Content 3, http://links.lww.com/
JTO/A807). In sharp contrast, in LATS1-expressing H2452 
cells, the YAP was localized diffusely in the cytoplasm. 
Knockdown of LATS1 induced nuclear translocation of 
YAP (Supplementary Fig. 5, Supplemental Digital Content 
3, http://links.lww.com/JTO/A807) in H2452 cells, sup-
porting the contention that LATS1 regulates the localiza-
tion of YAP. Upon transfection with the wild-type LATS1 
construct, YAP was translocated into the cytoplasm and 
colocalized with LATS1 protein (middle, Fig. 2C), whereas 
YAP was retained in the nucleus in cells transfected with 
the LATS1–PSEN1 construct (bottom, Fig. 2C).
Wild-type LATS1 significantly suppressed the growth 
of MSTO-211H cells in adherent (Fig. 2D) and anchorage-
independent (Fig. 2E) colony formation assays, whereas 
LAST1–PSEN1 lacked cell growth-suppressive activity 
(Fig. 2D and E).
Inactivation of Hippo Signaling Proteins in MM
We next examined the expression and phosphoryla-
tion of 11 key Hippo signaling proteins in 19 MM cell lines 
(Fig. 3). All of the cell lines retained their expression of the 
KIBRA, SAV1, and TAZ proteins, but expression of the 
RASSF1, Merlin (NF2), LATS1, and LATS2 proteins was 
lost in 89% (17 of 19), 68% (13 of 19), 28% (5 of 18), and 
63% (12 of 19) of cell lines, respectively. Consistent with 
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FIGURE 3.  Inactivation of Hippo pathway proteins in 
malignant mesothelioma (MM) cell lines. Immunoblot 
analysis of KIBRA; SAV1; RASSF1; Merlin; phosphorylated 
MST (pMST), MST1, and MST2; phosphorylated LATS1 
(pLATS1), LATS1, and LATS2; and phosphorylated yes-
associated protein (p-YAP), TAZ, 14-3-3, and γ-tubulin 
(loading control) protein expression in 19 MM cases and 
Met-5A cells. Molecular masses (in kilodaltons) are shown 
on the right. Antibodies used are listed in Supplementary 
Table 8 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A805).
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the aforementioned genetic analysis, MSTO-211H cells 
expressed only the truncated form of LATS1 protein (marked 
as * in Fig. 3). Furthermore, phosphorylation of the serine 
909 residue of LATS1 (indicating the active status of LATS1) 
was detectable in only 46% (6 of 13) of cell lines expressing 
LATS1 protein.
Hippo Pathway Gene Mutations in MM
In-depth analysis of the aforementioned whole-exon 
sequence data that did not meet the selection criteria revealed 
nucleotide alterations in six Hippo pathway genes (NF2, 
LATS2, FAT1, FAT2, RASSF2, and RASSF6) in 75% (4 of 
6) of cell lines examined (NCI-H2052, MSTO-211H, ACC-
MESO-1, and ACC-MESO-4) (Supplementary Table 5, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A805). Two MM cell lines (H2052 and MESO-1) with NF2 
mutations did not express the Merlin protein (Fig. 3). CNVs 
(gain and loss) of Hippo pathway genes detected in the six 
cell lines are shown in Supplementary Table 6 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A805).
The entire exons and flanking regions of the 40 
Hippo pathway genes (listed in Supplementary Table 3, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A805) were sequenced in 23 paired samples of tumor and 
normal (lung) tissues from MM patients (Supplementary 
Table 2, Supplemental Digital Content 1, http://links.lww.
com/JTO/A805) using a NGS. Somatic mutations were 
detected in 35% (8 of 23) of patients and validated by Sanger 
sequencing (data not shown). The mutations were observed 
only in four genes (NF2, LATS2, RASSF1, and SAV1; Table 2) 
with a frequency of 22% (5 of 23), 17% (4 of 23), 4% (1 of 
23), and 4% (1 of 23), respectively (Table 2).
Activation of YAP and its Clinical Relevance
In this study, we revealed that Hippo signaling was 
blocked at various points at both the genetic and protein 
levels. It is anticipated that these events in common would 
lead to activation and nuclear translocation of the YAP. In the 
nucleus, YAP acts as an oncogenic transcriptional coactiva-
tor. In fact, 55% (24 of 44) of primary MMs showed nuclear 
staining for YAP (Fig. 4A). Silencing of YAP1 by RNA inter-
ference (Fig. 4B and 4C) inhibited the growth of MM cells 
(Fig. 4D).
Although we were unable to detect any demographic 
or prognostic significance of nuclear YAP expression or 
Hippo pathway gene mutations (Supplementary Table 7, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A805 and Supplementary Fig. 6, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A807), the high fre-
quency of Hippo pathway gene mutations emphasizes the 
importance of the pathway in the development of MM.
DISCUSSION
Deregulation of Hippo signaling has been shown 
to result in abnormal regulation of organ size and tissue 
regeneration in various animal models and is considered 
to be a molecular mechanism likely involved in carcino-
genesis.13 The evolutionally conserved pathway is a regu-
lator of cell growth, cell division, and apoptosis. Signals 
evoked by cell contact are transmitted from the cell mem-
brane to the nucleus through a core kinase cassette con-
sisting of MST1/2, SAV1, MOB1A/B, and LATS1/2.8 The 
MST1/2 kinases (homologues of Drosophila Hippo pro-
tein), which form a complex with the scaffold proteins 
SAV1 and MOB1A/B, phosphorylate and activate LATS1/2 
(Drosophila Warts). YAP (Drosophila Yorkie) is a coactiva-
tor for various transcriptional factors including TEADs.4,14 
The YAP phosphorylated by LATS1/2 kinases becomes 
segregated from the nucleus and loses its oncogenic tran-
scriptional activity.
In this study, using whole-exon and RNA sequencing, 
we first searched for genes mutated in MM. This unbiased 
sequencing approach led to identification of the LATS1–
PSEN1 fusion gene. LATS1 is a serine/threonine kinase that 
is reportedly downregulated in various human cancers.15 
LATS1 induces apoptosis, negatively regulates cell prolif-
eration, and promotes genetic stability, cell migration, and 
metastasis.15–17 Mice deficient in LATS1 have been shown 
to develop soft-tissue sarcomas and ovarian tumors.18 A 
large variety of LATS1 mutations have been deposited in 
TABLE 2.  Mutations of Hippo Pathway Genes Detected in 23 Primary Tumors
No. Gene Chr RefSeq cDNA Amino Acid Type Sample
1 NF2 22 NM_181825 c.A124T p.K42X Stopgain SNV CT-9T
NF2 22 NM_181825 c.A205T p.K69X Stopgain SNV CT-33T
NF2 22 NM_181825 c.545delA p.E182fs Frameshift deletion CT-19T
NF2 22 NM_181825 c.G949T p.E317X Stopgain SNV CT-13T
NF2 22 NM_181825 c.C1331G p.S444X Stopgain SNV CT-7T
2 LATS2 13 NM_014572 c.2726_2727del p.909_909del Frameshift deletion CT-11T
LATS2 13 NM_014572 c.A2260G p.M754V Nonsynonymous SNV CT-24T
LATS2 13 NM_014572 c.C1867T p.R623W Nonsynonymous SNV CT-20T
LATS2 13 NM_014572 c.1285_1299del p.429_433del Nonframeshift deletion CT-33T
3 RASSF1 3 NM_170713 c.G76A p.D26N Nonsynonymous SNV CT-20T
4 SAV1 14 NM_021818 c.823_830del p.275_277del Frameshift deletion CT-24T
SNV, single nucleotide variant; Chr, chromosome.
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the Cancer Genome Project database (http://cancergenome.
nih.gov/), but their functional significance remains to be 
elucidated. We found that the LATS1–PSEN1 fusion gene 
lacked the kinase activity and tumor suppressor activity. 
Unfortunately, neither LATS1 mutation nor the LATS1–
PSEN1 fusion gene was detectable in the limited number 
of clinical samples we analyzed (N = 44, data not shown). 
Recently, Guo et al.19 reported whole-exome sequencing 
analysis of MM, and they also found that LATS1 was rarely 
mutated in clinical samples. However, the initial discovery 
prompted us to determine the mutational spectrum of 40 
Hippo pathway genes using targeted exon sequencing. We 
found that the NF2, LATS2, RASSF1, and SAV1 genes were 
mutated with a frequency of 35% (8 of 23) overall (Table 2). 
Furthermore, expression of the RASSF1, Merlin (NF2), 
LATS1, and LATS2 proteins was lost in a large proportion 
of the MM cell lines (Fig. 3). The highly frequent downreg-
ulation of RASSF1 protein may be attributable to epigenetic 
mechanisms. The frequent loss of phosphorylated LATS1 
protein indicates the involvement of posttranslational mech-
anisms and may provide a novel clue for future therapeutic 
intervention.
The frequent alterations present in Hippo pathway 
molecules indicate the feasibility of targeting this pathway 
for therapeutic purposes. However, all the core kinase cas-
sette proteins have been shown to potentially act as tumor 
suppressors and cannot be considered as therapeutic targets. 
YAP is a candidate oncogene.20,21 Yokoyama et al.22 previ-
ously reported amplification of the chromosomal region that 
carries the YAP1 gene locus in MM. We found that 55% 
(24 of 44) of primary MMs showed activation of YAP (Fig. 
4A). This frequency is lower than, but comparable with that 
reported in a previous study.5 We also showed that YAP is 
involved in the regulation of MM cell growth (Fig. 4D). 
Elevated expression of YAP has been reported to corre-
late with the outcome of patients with hepatocellular and 
colorectal carcinomas,23,24 but nuclear YAP expression did 
not show any significant correlation with the outcome or 
demography of MM patients in this study. Unfortunately, 
YAP is a transcription cofactor whose activity is unlikely 
to be manipulated by small-molecule compounds. Future 
investigations to discover druggable targets (enzymes or 
kinases) in the pathway are highly anticipated, and we sug-
gest that a search be made for molecules in the nuclear com-
plex containing the YAP1 oncogene product.25
In summary, we have demonstrated frequent genetic 
and protein alterations of molecules constituting the Hippo 
pathway in MM. Our unbiased collection of genome datasets 
could provide novel insights into the pathogenesis of MM.
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